EnClear Therapies
PrivateLast Round
VC Round
Sep 4, 2024
Total Funding Raised
$13.3M
Company Overview
EnClear Therapies operates in Healthcare & Life Sciences and is based in Newburyport, Massachusetts. Its latest recorded funding round was a VC Round in September 2024.
EnClear Therapies is a biotechnology company that develops device-based therapies designed to treat neurological diseases. The company's platform removes toxic proteins from cerebrospinal fluid (CSF) and provides controlled delivery of therapeutics to the central nervous system.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EnClear Therapies Comparables
Compare EnClear Therapies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuroscience Innovative Technologies | 81% | |
| Pharaoh Neuro, Inc. | 78% | |
| Cognos Therapeutics Inc | 78% |
For institutional investors. Book with your work email.
EnClear Therapies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 4, 2024 | ||||
| Grant | Jan 1, 2024 | ||||
| Series A | Feb 19, 2020 | ||||
| Seed | Mar 14, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EnClear Therapies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Dolby Family Ventures | Series A |
| Thiel Capital | Seed |
| Founders Fund | VC Round |
| Thiel Bio | VC Round |
| Bioverge | Seed, VC Round |
| Presight Capital | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 27, 2024
Monthly visitors increased 207% MoM.
- Sep 4, 2024
Led by Sontag Innovation Fund and The Brain Tumor Investment Fund.
For institutional investors. Book with your work email.
EnClear Therapies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EnClear Therapies's valuation, stock price, and market status.
Is EnClear Therapies a public or private company?
EnClear Therapies is a private company.
What is the current stock price of EnClear Therapies?
EnClear Therapies is a private company, so its shares have no public market price. Caplight tracks EnClear Therapies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EnClear Therapies worth (valuation)?
Valuation information for EnClear Therapies is not publicly available.
Can I buy EnClear Therapies stock?
EnClear Therapies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EnClear Therapies's last funding round?
EnClear Therapies's most recent funding round was VC Round on September 4, 2024.
Who are the main investors in EnClear Therapies?
Key investors in EnClear Therapies include The Sontag Foundation, 20/20 HealthCare Partners.
Will EnClear Therapies IPO soon?
No public IPO plans have been announced for EnClear Therapies.
How can I track EnClear Therapies secondary market activity?
Caplight tracks bids, offers, and trades in EnClear Therapies's shares on secondary markets.